Changeflow GovPing Healthcare & Life Sciences Tetragenetics Anti-Kv1.3 Antibody Patent EP3452...
Routine Rule Added Final

Tetragenetics Anti-Kv1.3 Antibody Patent EP3452084A1

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3452084A1 for Tetragenetics, Inc., titled 'ANTI-KV1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF,' with a publication date of April 15, 2026. The patent covers anti-Kv1.3 antibodies and their production and use, classified under A61P 37/06 for autoimmune and inflammatory disease applications. Designated states include all 31 EPC contracting states across the European Union and beyond.

“ANTI-KV1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.

What changed

The European Patent Office published patent EP3452084A1, granted to Tetragenetics, Inc., covering anti-Kv1.3 antibodies and their methods of production and therapeutic use for treating autoimmune and inflammatory diseases. The patent is classified under IPC codes A61K 39/00, C07K 16/00, C07K 16/28, and A61P 37/06 (immunological disorders). Named inventors include Marien, Van der Woning, De Haard, Harriman, Collarini, Bednenko, Bisharyan, Papoyan, Cardarelli, Clark, Kahn, and Agrawal.

For pharmaceutical and biotechnology companies developing immunomodulatory therapies, this patent grants Tetragenetics enforceable exclusive rights in all 31 designated EPC contracting states, potentially blocking competing anti-Kv1.3 programs and creating opportunities for licensing or partnership discussions.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ANTI-KV1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF

Publication EP3452084A1 Kind: A1 Apr 15, 2026

Applicants

Tetragenetics, Inc.

Inventors

MARIEN, Lore, VAN DER WONING, Bas, DE HAARD, Hans, HARRIMAN, William, D., COLLARINI, Ellen, J., COLUSSI, Paul, BEDNENKO, Janna, BISHARYAN, Yelena, PAPOYAN, Ashot, CARDARELLI, Joanna, CLARK, Theodore, G., KAHN, R. Douglas, AGRAWAL, Alka

IPC Classifications

A61K 39/00 20060101AFI20191122BHEP C07K 16/00 20060101ALI20191122BHEP C07K 16/44 20060101ALI20191122BHEP A61P 37/06 20060101ALI20191122BHEP C07K 16/28 20060101ALI20191122BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent publication IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!